Skip to main content
Equibles
FULC logo

FULC

Fulcrum Therapeutics, Inc.
$3.50 -0.09 (-2.51%) At close · Jul 10
Market Cap
$235.22M
Shares
66,633,321

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.50 Open$3.59 Day$3.41–3.62 52W$2.83–15.74 Avg vol 30d4.0M Short int6.4M · 9.6% float · 1.5d Short vol18% Last earningsApr 27, 2026 DataJan 2020–Jul 2026 Filing10-Q · Apr 27
Up next
Next earnings call
Jul 13, 2026 Est · unconfirmed · this week
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Apr 27, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −58%
      below
      Price vs 50-day avg −31%
      below
      RSI (14) 35
      neutral
      MACD trend Positive
      52-week position 5%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return 0%
      trailing
      6-month return −66%
      trailing
      YTD return −69%
      this year
      Relative strength −75%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $5 › 200d $8 — 200d above 50d
      Institutional flow Distributing
      5 of 168 funds reported for Jun 30 · net -87.7K sh shares · +2 new
      Insider flow Distributing
      Net -$65.6K over 90 days · 100% sells
      Short interest Rising
      9.64% of float · ▲ +16.3% MoM · 1.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      168 holders — near 3-yr high, broad support
      Squeeze score 43
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −100%
      Y/Y
      EPS growth −638%
      Y/Y
      Free cash flow $-60.4M
      Balance sheet $197.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 99%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 7.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −58% Bearish
      Price vs 50-day avg
      −31% Bearish
      RSI (14)
      35 Neutral
      MACD trend
      Positive Bullish
      52-week position
      5% Bearish
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $5 › 200d $8 — 200d above 50d
      Institutional flow Distributing
      5 of 168 funds reported for Jun 30 · net -87.7K sh shares · +2 new
      Insider flow Distributing
      Net -$65.6K over 90 days · 100% sells
      Short interest Rising
      9.64% of float · ▲ +16.3% MoM · 1.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      168 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $3 Now $4 · 5% 52-wk high $16
      vs 200-day avg -58% vs 50-day avg -31%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      cash, cash equivalents, and marketable securities $333.3M first quarter of 2026 —
      HbF at baseline 7.1% Phase Ib PIONEER trial call —
      HbF at week 12 19.3% Phase Ib PIONEER trial call —
      patients with no VOCs during treatment period 7 Phase Ib PIONEER trial call —
      total patients evaluated for VOCs 12 Phase Ib PIONEER trial call —
      Mean absolute HbF increase from baseline at Week 12 (20 mg cohort) 12.2% PIONEER Phase 1b 20 mg cohort, Week 12 —
      Net proceeds from December 2025 public offering $164.2M December 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      FULC
      Fulcrum Therapeutics, Inc.
      this stock
      		$235.22M -69.1% -100.0% — 9.6%
      ONC
      BeOne Medicines Ltd.
      		 $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +9.5% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.63B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +8.2% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      168
      % held
      107.7%
      Reported
      5 of 168
      Top holder
      SUVRETTA CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      154
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.4M
      Days to cover
      1.5d
      Change
      +900.8K sh
      View
      Short Volume
      Short vol %
      18%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      19.4K
      Value
      $68.1K
      As of
      Jun 11, 2026
      View
      Off-Exchange
      Off-exchange %
      42.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$65.6K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-74.9M
      EPS diluted
      $-1.18
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 25, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $65.0K
      Shares
      18.0K
      Filed
      Jun 26, 2026
      View
      Exempt Offerings
      Offering
      $68.5M
      Filed
      Jun 11, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Apr 27, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      FULC -8.9% -0.3% -66.3% -4.4% -69.1%
      SPY +0.8% +2.0% +8.9% +0.7% +10.2%
      vs SPY -9.7% -2.3% -75.2% -5.0% -79.3%
      Key facts CIK 1680581 CUSIP 359616109 13F (30d) 5 filings 5 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)